AstraZeneca, Breast Cancer

DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
I'm A Breast Cancer Doctor. Here's What I Didn't Know — Until I Was Diagnosed Myself.
Having counseled thousands of patients through their breast cancer diagnosis, I was fully aware of how nondiscriminatory this ...
Onlymyhealth7d
Why Two People With The Same Cancer May Need Completely Different Treatments
Even with the same cancer diagnosis personalised treatments are essential due to variations in patient health cancer ...
Medscape1d
Drugmakers Are Limiting Cancer Patients’ Access to Financial Lifelines. Why?
Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...
New breast cancer drug given green light for NHS use
Breast Cancer Now said olaparib will be an ‘valuable alternative’ for patients with a certain type of secondary breast cancer ...
Hosted on MSN3d
Breast Cancer: What It Is, Symptoms, Types, Stages & Treatments
Susan G. Komen: Quality of Life After Breast Cancer Treatment. National Cancer Institute: Complementary and ...
Linda Nolan: Alarming increase in secondary breast cancer as expert explains why it's often missed
Alarming rates of secondary breast cancer are on the rise, with the figure increasing year on year since 2018 so it's more important than ever to know where it is most likely to occur and what to look ...
Mel Gibson's cancer treatment claims branded 'dangerous, cruel and irresponsible' by Canadian Cancer Society. Here's what to know
"During Joe Rogan’s podcast on Jan. 9, Mel Gibson promoted drugs that are not scientifically proven cancer treatments," the ...
Bayer menopause drug reduces hot flashes in breast cancer group
Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...
Science Daily13d
Approaches against metastatic breast cancer: mini-tumors from circulating cancer cells
Tumor cells circulating in the blood are the 'germ cells' of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy ...
American Cancer Society1d
Cancer Incidence Rate for Women Under 50 Rises Above Men's
Cancer incidence continues to rise for many common cancers—especially for women. The incidence rate for women younger than 50 ...